Thank you for helping ELSO disseminate information by entering your experience in the ELSO Registry as soon as ECMO is implanted - before the run is complete. Instructions for entering data in the Registry and COVID-19 addendum can be found on the Data Definitions page.

We recognize you cannot complete and submit the entire ELSO Registry case report form prior to completion of the ECMO run and discharge from the hospital, but we would still like to have the data you know now.

To address concerns about incomplete data we report three nested data sets to accommodate the fact that different patients will be at different stages of care (and thus have more or less incomplete data). Also when considering the data please understand that the data displayed is a real-time data stream and subject to change as more patient information is accrued and as centers update the ELSO Registry Case Report Form and the ELSO COVID-19 addendum.



COVID-19 Cases on ECMO in the ELSO Registry

Total COVID-19 Cases COVID-19
Suspected or Confirmed
4247
COVID-19
Confirmed Cases
4232
Total counts of COVID-19 confirmed patients and count of COVID-19 suspected but not confirmed by testing.

Patients who initiated ECMO at
least 90 days ago
COVID-19
Confirmed
3060
COVID-19
In-hospital Mortality
47%

Outcomes

COVID-19 ECMO counts by ELSO Chapter

Still on ECMO Still Hospitalized at ELSO Center Total (n)
All ELSO 610 833 4247
          North America 361 500 2809
          Europe 143 190 897
          Asia Pacific 18 22 58
          Latin America 47 62 178
          SWAAC 41 59 305
Reports counts of ECMO-supported suspected or confirmed COVID-19 cases by ELSO Chapter

Filters affect the data shown in the tables below:

Region

Patient Age



Pre-ECMO Patient Factors

Patient-level summaries of COVID ECMO runs. All categorical variables are given as ‘percentage (count)’
Total ARDS Cohort
Number cases 3060 2369
Age(years)
Median(IQR) 49(40,57) 50(41,58)
# observed 3060 2369
BMI, kg/m2
Median(IQR) 32(28,37) 32(28,38)
# observed 2821 2186
Sex
Male 72%(2215) 73%(1736)
Female 28%(843) 27%(632)
# observed 3058 2368
Race/Ethnicity
Black 14%(415) 13%(302)
White (Non-Hispanic) 29%(896) 28%(663)
Asian 12%(378) 11%(257)
Mid East, N African 4%(134) 5%(108)
Other 4%(110) 4%(84)
Unknown 4%(136) 4%(105)
Multiple 4%(124) 5%(110)
Hispanic 28%(867) 31%(740)
# observed 3060 2369
Pre-ECMO Comorbidities
No comorbidity 26%(783) 25%(594)
Cancer 2%(47) 2%(40)
Pregnancy 2%(68) 2%(48)
Immunocompromised 4%(110) 4%(91)
Diabetes 30%(904) 31%(727)
Pre-existing heart disease 4%(109) 3%(64)
Pre-existing lung disease 4%(115) 4%(87)
Pre-existing renal insuff. 3%(83) 3%(66)
Frailty 1%(17) 0%(11)
Asthma 10%(305) 10%(237)
BMI > 30 \mathrm{kg}/\mathrm{m}^2 50%(1515) 50%(1185)
Hypertension 31%(959) 33%(773)
# observed 3060 2369
Acute illness
ARDS 82%(2523) 100%(2369)
Acute heart failure 6%(189) 4%(90)
Myocarditis 2%(70) 1%(17)
Acute kidney injury 29%(891) 31%(730)
# observed 3060 2369
Pre-ECMO Cardiac Arrest
Yes 5%(160) 3%(80)
No 95%(2863) 97%(2259)
# observed 3023 2339
Pre-ECMO Co-Infection
No Co-infection 54%(1654) 52%(1229)
Bacterial pneumonia 39%(1182) 41%(980)
Co-viral infection 11%(348) 11%(260)
Blood stream infection 16%(477) 17%(401)
Urinary tract infection 7%(208) 8%(178)
# observed 3057 2366

Pre-ECMO Interventions

Support and therapies. All categorical variables are given as ‘percentage (count)’
PreECLS PreECLS
Number cases 3060 2369
Noninvasive ventilation
Noninvasive ventilation prior to intubation 68%(2078) 68%(1616)
BiPAP 27%(814) 26%(626)
CPAP 12%(357) 10%(242)
HFNC 44%(1351) 47%(1108)
# observed 3058 2367
Pre-ECLS intubation (days)
Median(IQR) 3.5(1.1,6.2) 3.8(1.4,6.5)
# observed 2655 2058
Ventilator mode
Conventional 97%(2759) 97%(2158)
# observed 2856 2222
PEEP, cm H2O
Median(IQR) 14.0(10.0,16.0) 14.0(12.0,16.0)
# observed 2556 2012
PIP, cm H2O
Median(IQR) 34.0(30.0,38.0) 35.0(30.0,39.0)
# observed 2040 1590
FiO2
Median(IQR) 1.00(0.90,1.00) 1.00(0.98,1.00)
# observed 2566 2006
PaO2/FiO2
Median(IQR) 70(58,92) 70(58,90)
# observed 2507 1962
PCO2
Median(IQR) 60(50,75) 61(51,75)
# observed 2622 2038
Pre-ECMO Support
Prone positioning 59%(1777) 61%(1437)
# observed 3020 2342
Neuromuscular blockers 73%(2205) 75%(1763)
# observed 3021 2339
Inhaled pulmonary vasodilators 32%(956) 35%(810)
# observed 3020 2342
Any vasoactive support 61%(1852) 60%(1406)
# observed 3019 2339
Norepinephrine 55%(1663) 55%(1285)
# observed 3019 2339
Therapies, Immunomodulators
Any therapy 85%(2610) 89%(2101)
Glucocorticoids 60%(1837) 62%(1473)
IVIG 2%(73) 2%(44)
Anti-cytokine 25%(754) 27%(630)
Lopinavir/Ritonavir 6%(189) 7%(163)
JAK inhibition 1%(17) 1%(14)
Chloroquine/hydroxychloroquine 25%(778) 26%(625)
Remdesivir 37%(1126) 40%(944)
# observed 3060 2369
Support type
Respiratory 95%(2910) 100%(2365)
Cardiac 4%(120) 0%(2)
ECPR 1%(30) 0%(2)
# observed 3060 2369

Patient Status & Complications

Outcomes
Total ARDS Cohort
Last known patient status
Discharged alive to home or acute rehabilitation 22%(660) 22%(518)
Discharged alive to long-term acute care or unspecified location 15%(472) 17%(397)
Discharged to another hospital 12%(365) 10%(232)
Remain in the hospital (discharged from ICU) 0%(9) 0%(6)
Remain in the ICU 5%(138) 5%(110)
In-hospital death 46%(1416) 47%(1106)
Tracheostomy 49%(1443) 50%(1156)
# observed 2954 2292
Select complications
Seizures 1%(20) 1%(16)
# observed 2959 2285
CNS infarction by US/CT/MRI 1%(40) 1%(25)
# observed 2959 2285
CNS hemorrhage by US/CT/MRI 6%(189) 7%(152)
# observed 2959 2285
Hemolysis 6%(187) 7%(154)
# observed 2959 2285
Oxygenator failure 11%(324) 12%(271)
# observed 2959 2285
Pump failure 1%(34) 1%(23)
# observed 2959 2285
Circuit change 15%(456) 15%(345)
# observed 2959 2285
Thrombosis/Clots in circuit component 4%(114) 4%(90)
# observed 2959 2285
Discharge location
Home 32%(486) 33%(376)
Transfer to LTAC or Rehab 17%(250) 19%(218)
Transfer to another hospital 24%(365) 20%(232)
Other/Unknown 5%(68) 3%(40)

ELSO Ownership, No Rights to Publication, Disclaimer

The Dashboard content has been compiled and reported from a variety of sources, is not independently verified by ELSO, and is subject to change without notice. ELSO and its authorized agents and contractors make no representations or warranties about the quality, content, completeness, suitability, adequacy, sequence, accuracy, or timeliness of such content. ELSO disclaims any responsibility for any inaccuracy, whether by inclusion or omission, on the Dashboard or the Site, and disclaims any responsibility for subsequent change or withdrawal of data shown on the Dashboard or the Site, which is subject to alteration without notice. ELSO disclaims any and all warranties regarding this information and all liability whatsoever relating thereto. Any person who uses information obtained from this Dashboard does so at his or her own risk.

The Dashboard is provided as a public service to facilitate real-time sharing of information during the COVID-19 crisis for educational purposes only by health practitioners. ELSO owns the compilation of all data, and its use or publication by any third party is strictly forbidden. Publication or representation of this information as if it were statistically significant or part of a scientific study is irresponsible and misleading.

The tables are consistent with the Lancet Publication article but the data presented here is real time

Barbaro RP, MacLaren G, Boonstra PS, Iwashyna TJ, Slutsky AS, Fan E, Bartlett RH, Tonna JE, Hyslop R, Fanning JJ, Rycus PT, Hyer SJ, Anders MM, Agerstrand CL, Hryniewicz K, Diaz R, Lorusso R, Combes A, Brodie D, the Extracorporeal Life Support Organization. Extracorporeal Membrane Oxygenation Support in COVID-19: The Registry Report from the Extracorporeal Life Support Organization. Lancet. 2020; [In Press].